Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Yongyong Kang

dblp:258/2841 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
0since 2021 · last 2019
—ORCID · none

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%

Topics — the 2 heaviest of 2, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › cancer genomics
tumor purity estimation
0.412019
MEpurity: estimating tumor purity using DNA methylation data · Bioinform. 2019
Bioinformatics and computational biology
cancer genomics
0.112019
MEpurity: estimating tumor purity using DNA methylation data · Bioinform. 2019

Methods — techniques the papers use, named apart from their topics

beta mixture model · 0.4
YearPublicationVenuePosition
2019 MEpurity: estimating tumor purity using DNA methylation data
abstract
MOTIVATION: Tumor purity is a fundamental property of each cancer sample and affects downstream investigations. Current tumor purity estimation methods either require matched normal sample or report moderately high tumor purity even on normal samples. It is critical to develop a novel computational approach to estimate tumor purity with sufficient precision based on tumor-only sample. RESULTS: In this study, we developed MEpurity, a beta mixture model-based algorithm, to estimate the tumor purity based on tumor-only Illumina Infinium 450k methylation microarray data. We applied MEpurity to both The Cancer Genome Atlas (TCGA) cancer data and cancer cell line data, demonstrating that MEpurity reports low tumor purity on normal samples and comparable results on tumor samples with other state-of-art methods. AVAILABILITY AND IMPLEMENTATION: MEpurity is a C++ program which is available at https://github.com/xjtu-omics/MEpurity. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Xiaofei Yang 0003, Tingjie Wang, Jiadong Lin, Yongyong Kang, Peng Jia 0004, Kai Ye 0001
Bioinform.5